



Ha Dang



Lu Li



Tom Wallack




Kate Soukup

The Company

Kiralis is a pre-revenue startup founded in mid-2018. The company's vision is to enable the development of safer drugs and chemicals by providing access to pure enantiomers affordably and timely.

Kiralis offers several value propositions to customers in the Pharma, Agritech, Food, and Fragrance industries.



Our Project

Objective: Help Kiralis understand the value of its chiral-induced spin selectivity (CISS) technology, assess the costs involved, and identify potential partners.

- 1 Understand customers in the drug development and manufacturing industries
- 2 Assess the costs, challenges and opportunities in chiral molecule separation
- 3 Find potential partners in venture funds, CRO, bioinformatics,
- 4 Present findings and recommendations

Our Impact



Options for Profitability

- Partner with Pharmaceutical
- Partner with CROs
- Partner with Bioinformatics firms



Product Strategies

- Focus on Separation Technology
- Focus on Separation and Synthesis Technology



Misc. Findings

- Seek out pharma venture funds
- Provide project-based work
- Provide a continuous manufacturing process

